AGENUS INC (AGEN) Borrowing debt
- Total debt · latest quarter (USD): Value (m); Formula and calculation Current and noncurrent long-term debt plus complete reported short-term borrowings (commercial paper alone when no complete total is admitted). Period ending 2026-06-30..
- Net cash · latest quarter: Value (m); Formula and calculation Cash and cash equivalents plus current marketable securities less interest-bearing debt; negative net cash is displayed as net debt. Period ending 2026-06-30..
- Debt / assets · latest quarter: Value (m); Formula and calculation Current and noncurrent long-term debt plus complete reported short-term borrowings (commercial paper alone when no complete total is admitted) / total assets. Period ending 2026-06-30..
Borrowing debt
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Total debt · latest quarter (USD) | (m) | Current and noncurrent long-term debt plus complete reported short-term borrowings (commercial paper alone when no complete total is admitted). Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Net cash · latest quarter | (m) | Cash and cash equivalents plus current marketable securities less interest-bearing debt; negative net cash is displayed as net debt. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Debt / assets · latest quarter | (m) | Current and noncurrent long-term debt plus complete reported short-term borrowings (commercial paper alone when no complete total is admitted) / total assets. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Borrowing debt due within one year | 30.07M USD | Long-term Debt, Current Maturities |
| Borrowing debt due after one year | (m) | Long-term Debt, Excluding Current Maturities |
| Commercial paper | (m) | |
| Cash and current securities | (m) | Cash and Cash Equivalents, at Carrying Value |
| Borrowing debt | (m) | Long-term Debt, Current Maturities · Long-term Debt, Excluding Current Maturities |
| Total assets | 172.69M USD | Assets |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Total debt | Net cash / debt | Borrowing debt due within one year (USD) | Borrowing debt due after one year (USD) | Commercial paper (USD) | Cash and current securities (USD) | Total assets (USD) | Debt / assets |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | (m) | $30.07M | (m) | (m) | (m) | $172.69M | (m) |
| 2026-03-31 | (m) | (m) | $30.19M | (m) | (m) | (m) | $186.46M | (m) |
| 2025-12-31 | (m) | (m) | $44.66M | $0.00 | (m) | (m) | $226.80M | (m) |
| 2025-09-30 | (m) | (m) | $10.61M | $23.60M | (m) | (m) | $233.89M | (m) |
| 2025-06-30 | (m) | (m) | $10.72M | $23.15M | (m) | (m) | $185.22M | (m) |
| 2025-03-31 | (m) | (m) | $731.00K | $32.85M | (m) | (m) | $200.20M | (m) |
| 2024-12-31 | (m) | (m) | $2.70M | $30.47M | (m) | (m) | $226.27M | (m) |
| 2024-09-30 | (m) | (m) | $13.40M | $0.00 | (m) | (m) | $238.48M | (m) |
| 2024-06-30 | (m) | (m) | $13.43M | $0.00 | (m) | (m) | $292.42M | (m) |
| 2024-03-31 | (m) | (m) | $13.57M | $0.00 | (m) | (m) | $256.56M | (m) |
| 2023-12-31 | (m) | (m) | $146.00K | $12.77M | (m) | (m) | $313.91M | (m) |
| 2023-09-30 | (m) | (m) | $387.00K | $12.72M | (m) | (m) | $335.47M | (m) |
| 2023-06-30 | (m) | (m) | $622.00K | $12.67M | (m) | (m) | $383.59M | (m) |
| 2023-03-31 | (m) | (m) | $1.02M | $12.63M | (m) | (m) | $412.85M | (m) |
| 2022-12-31 | (m) | (m) | $575.00K | $12.58M | (m) | (m) | $413.56M | (m) |
| 2022-09-30 | (m) | (m) | $13.46M | (m) | (m) | (m) | $429.02M | (m) |
| 2022-06-30 | (m) | (m) | $13.70M | (m) | (m) | (m) | $456.17M | (m) |
| 2022-03-31 | (m) | (m) | $14.18M | (m) | (m) | (m) | $441.31M | (m) |
| 2021-12-31 | (m) | (m) | $728.00K | $12.82M | (m) | (m) | $465.96M | (m) |
| 2021-09-30 | (m) | (m) | $542.00K | $12.79M | (m) | (m) | $437.64M | (m) |
| 2021-06-30 | (m) | (m) | $838.00K | $18.95M | (m) | (m) | $192.30M | (m) |
| 2021-03-31 | (m) | (m) | $1.46M | $18.91M | (m) | (m) | $234.91M | (m) |
| 2020-12-31 | (m) | (m) | $833.00K | $18.88M | (m) | (m) | $214.51M | (m) |
| 2020-09-30 | (m) | (m) | $1.18M | $18.84M | (m) | (m) | $204.48M | (m) |
| 2020-06-30 | (m) | (m) | $1.53M | $18.81M | (m) | (m) | $185.78M | (m) |
| 2020-03-31 | (m) | (m) | $646.00K | $12.58M | (m) | (m) | $180.06M | (m) |
| 2019-12-31 | (m) | (m) | $646.00K | $13.38M | (m) | (m) | $155.34M | (m) |
| 2019-09-30 | (m) | (m) | $13.85M | (m) | (m) | (m) | $174.81M | (m) |
| 2019-06-30 | (m) | (m) | $13.68M | (m) | (m) | (m) | $206.71M | (m) |
| 2019-03-31 | (m) | (m) | $13.52M | (m) | (m) | (m) | $245.93M | (m) |
| 2018-12-31 | (m) | (m) | $146.06K | $13.21M | (m) | (m) | $136.40M | (m) |
| 2018-09-30 | (m) | (m) | $146.06K | $13.05M | (m) | (m) | $130.48M | (m) |
| 2018-06-30 | (m) | (m) | $146.06K | $12.91M | (m) | (m) | $131.94M | (m) |
| 2018-03-31 | (m) | (m) | $146.06K | $12.77M | (m) | (m) | $130.82M | (m) |
| 2017-12-31 | (m) | (m) | $20.64M | $142.39M | (m) | (m) | $138.40M | (m) |
| 2017-09-30 | (m) | (m) | $19.96M | $123.29M | (m) | (m) | $149.27M | (m) |
| 2017-06-30 | (m) | (m) | $146.06K | $138.53M | (m) | (m) | $176.49M | (m) |
| 2017-03-31 | (m) | (m) | $146.06K | $134.16M | (m) | (m) | $203.27M | (m) |
| 2016-12-31 | (m) | (m) | $146.06K | $130.54M | (m) | (m) | $156.99M | (m) |
| 2016-09-30 | (m) | (m) | $146.06K | $126.26M | (m) | (m) | $174.84M | (m) |
| 2016-06-30 | (m) | (m) | $146.06K | $122.13M | (m) | (m) | $196.45M | (m) |
| 2016-03-31 | (m) | (m) | $146.06K | $118.16M | (m) | (m) | $221.14M | (m) |
| 2015-12-31 | (m) | (m) | $146.06K | $114.33M | (m) | (m) | $242.23M | (m) |
| 2015-09-30 | (m) | (m) | $146.06K | $110.55M | (m) | (m) | $242.61M | (m) |
| 2015-06-30 | (m) | (m) | $146.06K | (m) | (m) | (m) | $180.11M | (m) |
| 2015-03-31 | (m) | (m) | $423.84K | (m) | (m) | (m) | $117.32M | (m) |
| 2014-12-31 | (m) | (m) | $1.26M | (m) | (m) | (m) | $74.53M | (m) |
| 2014-09-30 | (m) | (m) | $6.72M | (m) | (m) | (m) | $87.63M | (m) |
| 2014-06-30 | (m) | (m) | $7.43M | (m) | (m) | (m) | $100.19M | (m) |
| 2014-03-31 | (m) | (m) | $2.87M | (m) | (m) | (m) | $108.30M | (m) |
| 2013-12-31 | (m) | (m) | $3.52M | (m) | (m) | (m) | $34.84M | (m) |
| 2013-09-30 | (m) | (m) | $3.26M | (m) | (m) | (m) | $37.67M | (m) |
| 2013-06-30 | (m) | (m) | $2.43M | (m) | (m) | (m) | $21.37M | (m) |
| 2013-03-31 | (m) | (m) | $201.48K | (m) | (m) | (m) | $25.13M | (m) |
| 2012-12-31 | (m) | (m) | $204.09K | (m) | (m) | (m) | $29.09M | (m) |
| 2012-09-30 | (m) | (m) | $210.47K | (m) | (m) | (m) | $32.22M | (m) |
| 2012-06-30 | (m) | (m) | $212.47K | (m) | (m) | (m) | $33.27M | (m) |
| 2012-03-31 | (m) | (m) | $203.03K | (m) | (m) | (m) | $33.21M | (m) |
| 2011-12-31 | (m) | (m) | $197.68K | (m) | (m) | (m) | $19.81M | (m) |
| 2011-09-30 | (m) | (m) | $196.20K | (m) | (m) | (m) | $24.37M | (m) |
| 2011-06-30 | (m) | (m) | $146.06K | (m) | (m) | (m) | $22.23M | (m) |
| 2010-12-31 | (m) | (m) | $146.06K | (m) | (m) | (m) | $30.91M | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |